These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label Pfizer Inc. Ellence epirubicin NCT00140075 Cancer, Metastatic Breast Phase III http://www.pfizer.com/pfizer/download/uspi_ellence.pdf Clinical Study Summary Protocol No. 378-ONC-0030-184: Phase III, randomized study of epirubicin/cyclophosphamide followed by taxane (sequential chemotherapy) versus epirubicin/taxane (concurrent chemotherapy) as adjuvant treatment for operable, node-positive breast cancer. Deutsch M, Lambert-Falls R, Desch C, Zhou K, Perez E. Epirubicin combined with docetaxel or paclitaxel for node positive breast cancer, an exploratory analysis from a phase III study [abstract]. Breast Cancer Res Treat. 2006;100(suppl 1):S115. Abstract 2103. Lambert-Falls R, Deutsch MA, Desch C, Zhou K, Perez E. Phase III adjuvant trial of concurrent epirubicin/taxane vs. sequential epirubicin/cyclophosphamide followed by taxane for node positive breast cancer [abstract]. J Clin Oncol. 2006;24(suppl). Abstract 573. Link to ClinicalTrials.gov registration: http://www.clinicaltrials.gov/ct/show/NCT00140075?order=1 Pfizer will use reasonable efforts to include accurate and up-to-date information on the ClinicalStudyResults.org web site. However, because the status of studies often changes, Pfizer can make no, and makes no, warranties or representations of any kind as to the currency or completeness of the information contained therein. You agree that access to and use of information posted by Pfizer on the ClinicalStudyResults.org web site is at your own risk. Pfizer disclaims all warranties, express or implied, including warranties of merchantability of fitness for a particular purpose. Pfizer shall not be liable for any damages, including without limitation, direct, incidental, consequential, indirect or punitive damages, arising out of access to, use of, or inability to use information posted by Pfizer on the ClinicalStudyResults.org web site, or any errors or omissions in the content thereof. Company Study Protocol No. 378-ONC-0030-184 Back to Search Results